Müller T - Search Results

1

Role of dopamine agonists in Parkinson's disease therapy.

Woitalla D, Buhmann C, Hilker-Roggendorf R, Höglinger G, Koschel J, Müller T, Weise D. Woitalla D, et al. Among authors: muller t. J Neural Transm (Vienna). 2023 Jun;130(6):863-873. doi: 10.1007/s00702-023-02647-0. Epub 2023 May 11. J Neural Transm (Vienna). 2023. PMID: 37165120 Review.

2

The motor performance test series in Parkinson's disease is influenced by depression.

Kuhn W, Heye N, Müller T, Kraus P, Klotz P, Friedrich B, Welter FL, Przuntek H. Kuhn W, et al. Among authors: muller t. J Neural Transm (Vienna). 1996;103(3):349-54. doi: 10.1007/BF01271246. J Neural Transm (Vienna). 1996. PMID: 8739846 Clinical Trial.

3

Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis.

Kuhn W, Müller T, Winkel R, Danielczik S, Gerstner A, Häcker R, Mattern C, Przuntek H. Kuhn W, et al. Among authors: muller t. J Neural Transm (Vienna). 1996;103(10):1187-93. doi: 10.1007/BF01271203. J Neural Transm (Vienna). 1996. PMID: 9013405 Clinical Trial.

4

Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patients.

Kuhn W, Müller T, Gerlach M, Sofic E, Fuchs G, Heye N, Prautsch R, Przuntek H. Kuhn W, et al. Among authors: muller t. J Neural Transm (Vienna). 1996;103(12):1441-5. doi: 10.1007/BF01271258. J Neural Transm (Vienna). 1996. PMID: 9029411 Clinical Trial.

5

High prevalence of parkinsonism after occupational exposure to lead-sulfate batteries.

Kuhn W, Winkel R, Woitalla D, Meves S, Przuntek H, Müller T. Kuhn W, et al. Among authors: muller t. Neurology. 1998 Jun;50(6):1885-6. doi: 10.1212/wnl.50.6.1885. Neurology. 1998. PMID: 9633752

6

Plasma levels of R- and S-salsolinol are not increased in "de-novo" Parkinsonian patients.

Müller T, Sällström Baum S, Häussermann P, Woitalla D, Rommelspacher H, Przuntek H, Kuhn W. Müller T, et al. J Neural Transm (Vienna). 1998;105(2-3):239-46. doi: 10.1007/s007020050052. J Neural Transm (Vienna). 1998. PMID: 9660101 Clinical Trial.

7

Tolcapone and neurotoxicity in Parkinson's disease.

Kuhn W, Woitalla D, Gerlach M, Russ H, Müller T. Kuhn W, et al. Among authors: muller t. Lancet. 1998 Oct 17;352(9136):1313-4. doi: 10.1016/S0140-6736(05)70527-4. Lancet. 1998. PMID: 9788488 No abstract available.

8

Elevated plasma levels of homocysteine in Parkinson's disease.

Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, Büttner T, Woitalla D, Müller T. Kuhn W, et al. Among authors: muller t. Eur Neurol. 1998 Nov;40(4):225-7. doi: 10.1159/000007984. Eur Neurol. 1998. PMID: 9813406

9

Analysis of the parkin deletion in sporadic and familial Parkinson's disease. Short communication.

Krüger R, Vieira-Säcker AM, Kuhn W, Müller T, Woitalla D, Schöls L, Przuntek H, Epplen JT, Riess O. Krüger R, et al. Among authors: muller t. J Neural Transm (Vienna). 1999;106(2):159-63. doi: 10.1007/s007020050148. J Neural Transm (Vienna). 1999. PMID: 10226936

10

Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype.

Krüger R, Vieira-Saecker AM, Kuhn W, Berg D, Müller T, Kühnl N, Fuchs GA, Storch A, Hungs M, Woitalla D, Przuntek H, Epplen JT, Schöls L, Riess O. Krüger R, et al. Among authors: muller t. Ann Neurol. 1999 May;45(5):611-7. doi: 10.1002/1531-8249(199905)45:5<611::aid-ana9>3.0.co;2-x. Ann Neurol. 1999. PMID: 10319883

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,377 results

Search Page